Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Marker Therapeutics stock

Learn how to easily invest in Marker Therapeutics stock.

Marker Therapeutics Inc is a biotechnology business based in the US. Marker Therapeutics shares (MRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Marker Therapeutics employs 56 staff and has a trailing 12-month revenue of around $3 million.

How to buy shares in Marker Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRKR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Marker Therapeutics stock price (NASDAQ: MRKR)

Use our graph to track the performance of MRKR stocks over time.

Marker Therapeutics shares at a glance

Information last updated 2022-10-03.
Latest market close$0.40
52-week range$0.25 - $1.73
50-day moving average $0.37
200-day moving average $0.46
Wall St. target price$2.17
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.52

Buy Marker Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Marker Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Marker Therapeutics price performance over time

Historical closes compared with the close of $0.395 from 2022-10-05

1 week (2022-09-29) 5.78%
1 month (2022-09-06) 29.98%
3 months (2022-07-06) 9.81%
6 months (2022-04-05) -8.16%
1 year (2021-10-06) -76.06%
2 years (2020-10-06) -74.01%
3 years (2019-10-04) 4.85
5 years (2017-10-06) 3.2

Marker Therapeutics financials

Revenue TTM $3 million
Gross profit TTM $-26,553,169
Return on assets TTM -36.58%
Return on equity TTM -90.61%
Profit margin 0%
Book value $0.34
Market capitalisation $30.8 million

TTM: trailing 12 months

Marker Therapeutics share dividends

We're not expecting Marker Therapeutics to pay a dividend over the next 12 months.

Have Marker Therapeutics's shares ever split?

Marker Therapeutics's shares were split on a 1:12 basis on 16 September 2016. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marker Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Marker Therapeutics shares which in turn could have impacted Marker Therapeutics's share price.

Marker Therapeutics share price volatility

Over the last 12 months, Marker Therapeutics's shares have ranged in value from as little as $0.25 up to $1.73. A popular way to gauge a stock's volatility is its "beta".

MRKR.US volatility(beta: 1.25)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marker Therapeutics's is 1.2521. This would suggest that Marker Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Marker Therapeutics overview

Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas. .

Frequently asked questions

What percentage of Marker Therapeutics is owned by insiders or institutions?
Currently 20.261% of Marker Therapeutics shares are held by insiders and 27.24% by institutions.
How many people work for Marker Therapeutics?
Latest data suggests 56 work at Marker Therapeutics.
When does the fiscal year end for Marker Therapeutics?
Marker Therapeutics's fiscal year ends in December.
Where is Marker Therapeutics based?
Marker Therapeutics's address is: 3200 Southwest Freeway, Houston, TX, United States, 77027
What is Marker Therapeutics's ISIN number?
Marker Therapeutics's international securities identification number is: US57055L1070
What is Marker Therapeutics's CUSIP number?
Marker Therapeutics's Committee on Uniform Securities Identification Procedures number is: 57055L107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site